Roxithromycin

Roxithromycin (RU-28965) is an orally active semi-synthethic macrolide antibiotic. Roxithromycin inhibits protein biosynthesis in the elongation step by binding to 50S bacterial ribosome. Roxithromycin has antimicrobial, antiproliferative, anti-inflammatory, tumour vasculature inhibiting and lung injury ameliorating effects[1][2][3][4][5][6][7][8][9][10][11].

Product Specifications

CAS Number

[80214-83-1]

Product Name Alternative

RU-28965

UNSPSC

12352005

Hazard Statement

H410

Target

Antibiotic; Apoptosis; Bacterial; NF-κB; p38 MAPK

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; MAPK/ERK Pathway; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/roxithromycin.html

Purity

99.86

Solubility

DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

Smiles

C[C@H]([C@H]([C@](O)(C[C@H](/C1=N\OCOCCOC)C)C)O[C@@](O[C@H](C)C[C@@H]2N(C)C)([H])[C@@H]2O)[C@]([C@H](C(O[C@@H]([C@@](O)([C@H](O)[C@H]1C)C)CC)=O)C)([H])O[C@@](O[C@@H](C)[C@@H]3O)([H])C[C@@]3(C)OC

Molecular Formula

C41H76N2O15

Molecular Weight

837.05

Precautions

H410

References & Citations

[6]Yatsunami J, et al. Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett. 1998 Sep 25;131 (2) :137-43. |[7]Ito T, et al. Roxithromycin inhibits chemokine-induced chemotaxis of Th1 and Th2 cells but regulatory T cells. J Dermatol Sci. 2009 Jun;54 (3) :185-91.|[8]Takahashi H, et al. Roxithromycin decreases ultraviolet B irradiation-induced reactive oxygen intermediates production and apoptosis of keratinocytes. J Dermatol Sci. 2004 Feb;34 (1) :25-33. |[9]Zhang X, et al. Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells. Acta Pharmacol Sin. 2021 Dec;42 (12) :2058-2068.|[10]Ueno S, et al. Roxithromycin inhibits constitutive activation of nuclear factor {kappa}B by diminishing oxidative stress in a rat model of hepatocellular carcinoma. Clin Cancer Res. 2005 Aug 1;11 (15) :5645-50. |[11]Ci X, et al. Short-term roxithromycin treatment attenuates airway inflammation via MAPK/NF-κB activation in a mouse model of allergic asthma. Inflamm Res. 2012 Jul;61 (7) :749-58. |[1]Duewelhenke N, et al. Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agents Chemother. 2007 Jan;51 (1) :54-63.|[2]Takakusagi K, et al. Multimodal biopanning of T7 phage-displayed peptides reveals angiomotin as a potential receptor of the anti-angiogenic macrolide Roxithromycin. Eur J Med Chem. 2015 Jan 27;90:809-21. |[3]Yamazaki H, et al. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26 (11) :1053-7.|[4]Bertho G, et al. Transferred nuclear Overhauser effect study of macrolide-ribosome interactions: correlation between antibiotic activities and bound conformations. Bioorg Med Chem. 1998 Feb;6 (2) :209-21.|[5]Chantot JF, et al. Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo) . 1986 May;39 (5) :660-8.